Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding ...

Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, ...

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies.

Market is undergoing a transformative phase, driven by the increasing demand for precision medicine and targeted therapies.

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...

New research has revealed the potential of engineered proteins to more precisely deliver drugs within the body.

The matter was discussed during the 92nd DTAB meeting held on April 24, 2025. The Board was apprised with respect to ...

A new publication shines a spotlight on HER3, a long-overlooked member of the ErbB receptor family, revealing its critical role in cancer progression and resistance to therapy.

Corbus Pharmaceuticals Holdings, Inc.’s CRBP share price has surged by 5.55%, which has investors questioning if this is ...

New research led by the University of Sydney has revealed the potential of engineered proteins to more precisely deliver ...